LogoCrystal's MCW Coder Hub

30903

37 min read

👩🏾‍⚕️CPT Code 30903 — Control Nasal Hemorrhage, Anterior, Complex (Extensive Cautery and/or Packing) Any Method

Code Description

Official CPT Description: Control nasal hemorrhage, anterior, complex (extensive cautery and/or packing) any method

CPT 30903 reports the treatment of an active anterior nasal hemorrhage (epistaxis) using an extensive or complex approach involving significant cautery, aggressive or layered packing, or both. This code represents the more resource-intensive tier of anterior epistaxis control and is distinguished from its simpler counterpart CPT 30901 primarily by the degree of difficulty, the amount of intervention required, and the extent of the technique employed to achieve hemostasis.

There are three critical elements embedded in the code descriptor that collectively define its appropriate use:

First — anterior location. CPT 30903 applies specifically when the bleeding originates from the anterior portion of the nasal cavity. Anterior epistaxis sources — most commonly Kiesselbach’s plexus on the anterior nasal septum — account for the vast majority of nosebleed presentations and are generally accessible via direct visualization through the naris using a nasal speculum and headlight, without requiring specialized posterior nasal packing equipment. Posterior epistaxis, which originates deeper in the nasal cavity near the sphenopalatine arterial territory, is coded separately using 30905 (initial) and 30906 (subsequent).

Second — complex / extensive nature. This is the most nuanced aspect of 30903 and the most frequent source of coding confusion. CPT does not provide a precise, numerically defined threshold distinguishing “simple” (30901) from “complex” (30903). The determination rests on the provider’s professional judgment and on documentation that reflects the level of difficulty encountered. Indicators of complexity that support 30903 over 30901 include: multiple failed attempts to achieve hemostasis, use of more than one treatment modality in the same encounter, application of layered or multiple-pass packing, bleeding from more than one site within the same nasal cavity, unusually brisk or arterial-type bleeding requiring more aggressive intervention, deeper bleeding sources within the anterior cavity requiring extensive instrumentation, and use of high-volume topical agents with prolonged contact times before achieving control.

Third — any method. The descriptor explicitly states “any method,” confirming that 30903 encompasses all currently employed techniques for anterior epistaxis control, including chemical cauterization with silver nitrate, electrocauterization (bipolar or monopolar), thermal cautery, traditional gauze packing with petroleum jelly-impregnated strips, prefabricated polyvinyl acetate (PVA) sponge packs (e.g., Merocel), inflatable epistaxis balloons, oxidized cellulose hemostatic agents (Surgicel, Gelfoam), and topical thrombin agents — provided the overall effort reflects extensive rather than limited intervention.

This code is unilateral by nature. When both sides of the nose require complex anterior hemorrhage control, Modifier 50 (or RT/LT per payer preference) is required. When different levels of intervention are performed on each side in the same encounter (e.g., complex on the left, simple on the right), each side is billed separately with appropriate laterality and/or Modifier 59/XS — see Coding Examples below.

Anatomy & Clinical Context

The nasal cavity is divided into right and left passages by the nasal septum. The blood supply to the nasal cavity is rich and dual-sourced, arising from both the internal carotid system (via the anterior and posterior ethmoidal arteries off the ophthalmic artery) and the external carotid system (via the sphenopalatine and greater palatine arteries off the maxillary artery).

Kiesselbach’s Plexus (Little’s Area) is the primary source of anterior epistaxis. Located on the anteroinferior nasal septum approximately 1-2 cm inside the naris, this vascular anastomotic network represents the convergence of terminal branches from multiple arterial systems: the anterior ethmoidal artery, the superior labial artery (a branch of the facial artery), the greater palatine artery, and branches of the sphenopalatine artery. Because multiple arterial systems contribute to this plexus, bleeding can be brisk and difficult to control even when the source is anterior and visible. The overlying mucosa here is thin, poorly supported, and susceptible to desiccation, trauma, and mucosal atrophy — all of which predispose to recurrent epistaxis.

Anterior vs. Posterior Distinction: The clinical determination of anterior versus posterior bleeding is important not only for treatment selection but for correct CPT code assignment. Anterior bleeding is typically visible with a nasal speculum and headlight, is unilateral, and does not demonstrate active blood flow from the posterior nasopharynx. Posterior bleeding is typically not visible on anterior rhinoscopy, may be bilateral, and often presents with blood flowing down the posterior pharynx. When bleeding cannot be controlled with anterior measures, posterior packing is required and the procedure escalates to CPT 30905.

Woodruff’s Plexus, located on the posterior lateral nasal wall just anterior to the posterior end of the inferior turbinate, is the primary source of posterior epistaxis. Treatment of this source with posterior packing or cautery is reported with 30905, not 30903.

Sphenopalatine Artery Territory: Recurrent or refractory posterior-origin epistaxis ultimately may require surgical ligation or endoscopic cauterization of the sphenopalatine artery (CPT 30901 or 31238 depending on approach — see code tree below), which is a fundamentally different and more invasive procedure than anterior packing.

Procedure Overview

Common Techniques and Methods for CPT 30903 (Complex Anterior Epistaxis Control):

Preparation and Anesthesia: Cotton pledgets or cotton strips soaked in a mixture of a topical vasoconstrictor (oxymetazoline 0.05%, epinephrine 1:1000, or cocaine 4%) and a topical anesthetic (4% lidocaine or pontocaine) are placed into the anterior nasal cavity and left in contact with the mucosa for 5-15 minutes. This achieves both vasoconstriction (to slow the bleeding and improve visualization) and topical anesthesia. If the pledgets are placed and removed with no further intervention required and bleeding has spontaneously stopped, the encounter is reported with an E/M code only — not 30901 or 30903 — because no cautery or packing was left in place.

Chemical Cauterization: A silver nitrate applicator stick is applied directly to the identified bleeding point and held in contact for 3-5 seconds until a gray-white eschar forms. For complex cases, multiple applications may be required to seal the bleeding vessel, or two or more separate bleeding points within the anterior cavity may require individual cauterization. The complexity may also arise from the location of the bleeder (deeper in the anterior cavity, requiring more extensive instrumentation to reach) or from the briskness of the bleed obscuring the site.

Electrocauterization: Monopolar or bipolar electrocautery delivered via a fine-tip nasal cautery probe achieves hemostasis through controlled thermal desiccation of the bleeding vessel. This technique is often used when chemical cauterization fails or when the bleeding site is on a larger, more robust vessel. For 30903, documentation should reflect that more than a single application was required, or that the technique involved extended visualization and multiple treatment applications.

Anterior Nasal Packing: When direct cauterization is unsuccessful or insufficient, anterior nasal packing is placed to apply sustained tamponade pressure to the nasal mucosa. Packing types include:

  • Traditional ribbon gauze (petroleum jelly-impregnated, 0.5-inch or 1-inch width): Layered in an accordion fashion from the floor of the nasal cavity superiorly, building up to fill the entire anterior nasal vault. This is among the most uncomfortable and technically involved packing techniques and clearly represents “extensive” intervention.
  • Absorbable hemostatic packing (Surgicel, Gelfoam, Merocel with thrombin): Bioabsorbable materials that achieve hemostasis through hemostatic and pressure mechanisms without requiring removal.
  • Pre-formed nasal tampons (Merocel/PVA sponge): Compressed dehydrated sponge inserted in dry form and then hydrated in place, expanding to fill the nasal cavity and apply tamponade. For complex cases, more than one sponge or additional packing layers may be required.
  • Epistaxis balloons (RhinoRocket, Rapid Rhino): Inflatable balloon devices that exert circumferential pressure on the nasal mucosa. A single balloon constitutes the primary packing in many practices.

Important

For CPT 30903, the “extensive” nature of the packing is established when more than one packing type is used, when layered or supplemental packing is required, when initial packing fails and replacement or augmentation is performed, or when the total time and effort are substantially greater than a straightforward single-sponge insertion.

ICD-10-CM Diagnosis Codes

The correct ICD-10-CM code for epistaxis is R04.0 in the overwhelming majority of cases. This is a relatively simple diagnosis code assignment from a classification standpoint, but several nuances apply that have significant compliance implications.

Primary Epistaxis Code

  • R04.0 — Epistaxis. This is the sole ICD-10-CM code specifically designated for nosebleed/epistaxis. It does not carry laterality specification (right vs. left) within the code itself — laterality for billing purposes is conveyed via CPT modifiers (RT/LT), not ICD-10-CM. R04.0 is classified within the “Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified” chapter (R00-R99). Per ICD-10-CM Official Guidelines, R04.0 should NOT be used as the principal diagnosis when a related definitive diagnostic condition that caused the epistaxis has been established and documented. In that case, the underlying causal condition becomes the principal diagnosis.

ICD-10-CM Guideline Note — Symptom vs. Definitive Diagnosis: When the physician documents the underlying cause of the epistaxis in the medical record, that underlying condition should be coded as the primary diagnosis, with R04.0 as an optional secondary code for clarity. If the documentation states only “epistaxis” without specifying an underlying cause, R04.0 stands alone as the principal diagnosis for the encounter.

When R04.0 Is Secondary — Underlying Condition as Principal Diagnosis:

  • I10 — Essential (primary) hypertension. This is the single most common underlying condition associated with epistaxis in adults. When the physician explicitly documents that the epistaxis was precipitated by or is related to hypertension, I10 should be sequenced as the primary diagnosis and R04.0 as secondary. Simply having hypertension on the problem list while presenting for nosebleed does not automatically make I10 the principal diagnosis — the clinical documentation must establish the causal relationship. This is one of the most frequently debated sequencing decisions in epistaxis coding.
  • I78.0 — Hereditary hemorrhagic telangiectasia (HHT / Osler-Weber-Rendu syndrome). HHT is a genetic vascular disorder causing recurrent, often bilateral, severe nasal telangiectasia-based epistaxis. This is the principal diagnosis in HHT patients presenting for epistaxis control; R04.0 is secondary.
  • D68.9 — Coagulation defect, unspecified. Or use the specific coagulopathy when documented (e.g., D68.312 for acquired hemophilia, D66 for hemophilia A, D67 for hemophilia B).
  • D69.3 — Immune thrombocytopenic purpura. Or D69.41 (Evans syndrome), D69.51 (primary thrombocytopenia), etc.
  • T45.515A — Adverse effect of anticoagulants, initial encounter. Used when the epistaxis is an adverse effect of therapeutic anticoagulant use (warfarin, heparin, LMWH). Code the adverse effect T code with appropriate encounter character, followed by the anticoagulant and the epistaxis R04.0.
  • T45.525A — Adverse effect of antithrombotic/antiplatelet drugs, initial encounter (e.g., aspirin, clopidogrel, ticagrelor-related epistaxis).
  • D68.32 — Hemorrhagic disorder due to extrinsic circulating anticoagulants. For warfarin-associated epistaxis with therapeutic anticoagulant overuse.

Post-operative Epistaxis:

  • T88.8XXA — Other specified complications of surgical and medical care, not elsewhere classified, initial encounter. When the epistaxis is a post-operative complication of a prior nasal or sinus procedure (e.g., post-septoplasty or post-FESS bleeding), do NOT use R04.0. The correct code is T88.8XXA linked to the CPT procedure code that caused the complication, per ICD-10-CM complication coding guidelines. This is a frequently cited coding error in ENT practices.

Traumatic Epistaxis:

  • S09.91XA — Unspecified injury of nose, initial encounter.
  • S00.31XA — Abrasion of nose, initial encounter.
  • S01.21XA — Laceration without foreign body of nose, initial encounter. The appropriate injury code becomes the principal diagnosis when trauma is the documented cause of the epistaxis.

Hereditary and Structural Causes:

  • J34.89 — Other specified disorders of nose and nasal sinuses. Used for structural nasal conditions predisposing to epistaxis (e.g., nasal septal deviation with recurrent bleeding from a spur, or nasal angiofibroma not captured by another specific code).
  • D47.01 — Mast cell neoplasm. Rare systemic conditions causing vascular fragility.

ICD-10-PCS Crosswalk (Inpatient Facility)

In the inpatient setting, ICD-10-PCS codes replace CPT codes. Epistaxis control in the inpatient setting has generated significant coding guidance from the American Hospital Association Coding Clinic, and the correct PCS root operation depends critically on the specific method used. This is one of the more nuanced areas of ICD-10-PCS coding for ENT procedures.

The Root Operation Decision — Control vs. Packing vs. Destruction:

This three-way decision tree is the most important coding concept in inpatient epistaxis PCS coding and is guided by PCS Guideline B3.7 (which states that when a more definitive root operation is available to specify the method, use that more definitive root operation rather than Control).

Control (3) — Stopping or attempting to stop acute bleeding: Control is the appropriate root operation when the physician performs general non-specific hemostatic measures to stop acute bleeding — such as suturing a laceration, applying pressure, or performing general electrocautery without ablating a specific vascular structure or tissue as the primary objective. The body system and body part selected reflect the region where bleeding is controlled. Per 4th Qtr 2017 Coding Clinic guidance, when a suture is used to stop nosebleed, Control is the correct root operation.

  • 0W3Q7ZZ — Control Bleeding in Respiratory Tract, Via Natural or Artificial Opening. This code is applicable when hemorrhage control is performed using general hemostatic measures (suture, pressure, non-specific cautery) and none of the more specific root operations below apply. It is the broadest ICD-10-PCS code for anterior nasal bleeding control and encompasses scenarios where the clinician stops bleeding without a precise anatomically targeted intervention.

Packing (2Y41X52) — Anatomy/Physiology Table: When nasal packing is the primary method used — the physician inserts material into the nasal cavity that is left in place to achieve tamponade — PCS Guideline B3.7 directs the coder to use the more specific Packing root operation rather than Control. Nasal packing falls within the Anatomical Regions section of ICD-10-PCS (section 2, Placement), not the Medical and Surgical section.

  • 2Y41X52 — Packing of Nasal Region using Packing Material, External Approach. This is the correct PCS code when a nasal tampon, ribbon gauze, or other packing material is inserted into the anterior nasal cavity and left in place to control hemorrhage. It represents Placement (2), Anatomical Regions (Y), Packing (4), Nasal Region (1), External Approach (X), Packing Material (5), No Qualifier (2). Per 4th Qtr 2017 Coding Clinic, this is the preferred code over the Control root operation when packing is the specific technique employed.

Destruction (5) — Ablation of a body part: When cauterization of a specific vascular structure or tissue is performed as the primary objective (not simply to stop acute bleeding, but to destroy a specific named vessel or tissue such as a nasal telangiectasia in HHT, or a known bleeding polyp), PCS Guideline B3.7 again directs toward the more specific Destruction root operation. Per a published MMP, Inc. ICD-10-PCS guidance analysis, when a physician cauterizes a specific identifiable nasal structure (e.g., turbinate, nasal septum vessel), Destruction is used.

  • 09590ZZ — Destruction of Nasal Septum, Open Approach. Used when the documented purpose of cauterization is destruction of a specific septal vascular lesion or telangiectasia, not merely stopping acute bleeding.
  • 09593ZZ — Destruction of Nasal Septum, Percutaneous Approach. Used when the approach is percutaneous (e.g., sclerotherapy injection or fine-needle cautery probe inserted through the mucosa).

PCS Code Summary for Epistaxis Control — Decision Guide:

The correct PCS code selection follows this hierarchy, as guided by ICD-10-PCS Guideline B3.7 and AHA Coding Clinic:

  1. If packing material is inserted and left in place → 2Y41X52 (Packing)
  2. If specific tissue/vessel is cauterized/destroyed as the primary objective → 09590ZZ or 09593ZZ (Destruction)
  3. If neither packing nor specific destruction is performed (e.g., pressure, suture, general electrocautery to stop acute bleeding as the primary objective) → 0W3Q7ZZ (Control)

DRG Impact of PCS Code Selection: This distinction has real DRG impact. The Destruction codes (09590ZZ, 09593ZZ) are OR-designated procedures in the MS-DRG grouper, which means they trigger a surgical DRG. The Packing code (2Y41X52) and the Control code (0W3Q7ZZ) are non-OR procedures, which means they do NOT trigger a surgical DRG on their own. Cases with only non-OR epistaxis procedure codes will group to a medical DRG based on the principal diagnosis and CC/MCC burden.

MS-DRG Assignment

CPT 30903 is predominantly an outpatient, office, or emergency department procedure. However, patients with severe or refractory epistaxis are occasionally admitted to the inpatient setting — particularly when epistaxis is related to a serious underlying coagulopathy, when the patient requires transfusion for blood loss, when posterior packing is in place and the patient requires monitoring, or when the epistaxis is a post-operative complication of a recent surgical procedure.

In the inpatient setting, the DRG is driven by the principal diagnosis (the condition established after study to be chiefly responsible for the admission) and the presence of CCs and MCCs. The epistaxis itself (R04.0) is typically not the principal diagnosis in admitted patients — rather, it is the underlying cause (coagulopathy, malignancy, HHT, hypertensive urgency) that drives DRG assignment.

MDC 03 — Ear, Nose, Mouth and Throat (when epistaxis / nasal disorder is principal diagnosis):

  • MS-DRG 154 — Other Ear, Nose, Mouth and Throat Diagnoses with MCC
  • MS-DRG 155 — Other Ear, Nose, Mouth and Throat Diagnoses with CC
  • MS-DRG 156 — Other Ear, Nose, Mouth and Throat Diagnoses without CC/MCC

When Underlying Coagulopathy or Blood Disorder Is Principal Diagnosis:

  • MS-DRG 812 — Red Blood Cell Disorders with MCC
  • MS-DRG 813 — Red Blood Cell Disorders without MCC
  • MS-DRG 826 — Myeloproliferative Disorders or Poorly Differentiated Neoplasms with MCC/CC
  • MS-DRG 791 — Prematurity with Major Problems (for pediatric coagulopathy-related epistaxis, not applicable in most adult cases)

When HHT (I78.0) or Hereditary Coagulopathy Is Principal Diagnosis:

  • MS-DRG 827 — Myeloproliferative Disorders or Poorly Differentiated Neoplasms with MCC
  • HHT cases may group to MDC 05 (Circulatory) or MDC 03 depending on the primary manifestation and the DRG grouper logic applied to I78.0 specifically.

When Hypertensive Crisis / Urgency Is Principal:

  • MS-DRG 304 — Hypertension with MCC
  • MS-DRG 305 — Hypertension with CC
  • MS-DRG 306 — Hypertension without CC/MCC

Surgical DRG Triggered by ENT OR Procedure (if Destruction PCS codes assigned):

  • MS-DRG 133 — Other Ear, Nose, Mouth and Throat O.R. Procedures with CC/MCC
  • MS-DRG 134 — Other Ear, Nose, Mouth and Throat O.R. Procedures without CC/MCC

Note on CC/MCC Capture in Epistaxis Admissions: In the inpatient setting, epistaxis admissions frequently involve patients with multiple comorbidities that qualify as CCs or MCCs. Anticoagulant use and adverse effects (T45.515A), coagulopathy diagnoses (D68.x, D69.x), anemia requiring transfusion (D64.9, Z51.3 for blood transfusion), malnutrition (E43, E44.x), and hypertensive heart disease (I11.x) are all common concomitant diagnoses in epistaxis patients that must be captured comprehensively to optimize DRG weight.

wRVU and Reimbursement

  • Work RVU (wRVU): 3.00 (finalized by CMS effective CY 2018 following AMA RUC review; maintained at this level through 2025)
  • Global Period: 0 days
  • 2025 Medicare Conversion Factor: $32.35
  • Approximate 2025 Medicare Facility Payment: ~100
  • Approximate 2025 Medicare Non-Facility (Office) Payment: ~160. The non-facility rate is substantially higher because it includes a practice expense component for supplies (packing materials, cautery instruments, topical agents) that are consumed in the physician’s office setting. In the facility setting (ED, hospital), these supplies are billed separately by the facility.
  • Comparison within the epistaxis family: 30901 (simple anterior) carries approximately 1.62 wRVU; 30903 (complex anterior) carries 3.00 wRVU; 30905 (posterior, initial) carries approximately 3.01 wRVU; 30906 (posterior, subsequent) carries approximately 3.88 wRVU.

The 0-day global period for 30903 means that the fee covers only the day of the procedure itself. Any subsequent encounter — including a return visit the next day to change or remove nasal packing, assess healing, or manage a recurrent bleed — is separately billable. This is clinically significant because nasal packing (particularly traditional ribbon gauze or PVA sponge packs) is typically removed 2-4 days after placement, and that removal visit is separately billable as an E/M service or, if a new bleed is encountered and controlled at that visit, as a separate epistaxis control code.

AMA RUC History: CPT 30903 was identified by the AMA RUC as potentially misvalued in 2017. The American Rhinologic Society (ARS), in coordination with the AAO-HNS, conducted provider surveys and presented data to the RUC to defend the existing values. CMS ultimately finalized the 3.00 wRVU for CY 2018 and has maintained it subsequently. This is a relatively unusual outcome in the era of widespread RVU reductions and reflects the strong advocacy work of the rhinology specialty societies for this code family.

Assistant Surgeon

CPT 30903 has an assistant surgeon indicator of 0 under Medicare — assistant surgery is not payable. This is a single-operator procedure that does not require a second surgical operator. Nursing or medical assistant support may be provided at the bedside during the procedure, but this does not constitute assistant surgery billing. Commercial payers follow the same convention.

HCC Relevance

CPT 30903 is a procedure code and carries no direct HCC mapping. R04.0 (Epistaxis), the primary diagnosis code for most 30903 encounters, is also not an HCC-mapped code and does not contribute to CMS risk-adjustment scores.

However, the underlying conditions that predispose patients to complex epistaxis are frequently HCC-mapped, and comprehensive diagnosis reporting at each epistaxis encounter — including all contributing comorbidities — is important for accurate risk adjustment in managed care and value-based care arrangements:

  • I78.0 (HHT) — Not directly HCC-mapped, but patients with HHT often carry additional vascular and pulmonary comorbidities that are HCC-relevant.
  • I10 (Essential hypertension) with hypertensive heart disease (I11.x) — HCC 85 (Hypertensive Heart Disease). Documenting the relationship between hypertension and heart disease when both are present contributes to HCC capture. Hypertension alone (I10) without organ damage is not HCC-mapped.
  • D68.x (Coagulopathy) — Depending on the specific code, some coagulation defect codes may not map to HCC; however, hemophilia (D66, D67) does map to HCC 46 (Coagulation Defects and Other Specified Hematological Disorders).
  • D69.3 (ITP) — maps to HCC 46.
  • C34.x, C61, C67.x (Active malignancy) — When epistaxis is a complication of malignancy-related thrombocytopenia from chemotherapy, the active cancer codes are high-weight HCC codes that must be captured at every encounter.
  • T45.515A (Adverse effect of anticoagulants) — not HCC-mapped, but confirms anticoagulant therapy, which may support documentation of the underlying condition requiring anticoagulation (e.g., atrial fibrillation → HCC 96; venous thromboembolism → not HCC-mapped but clinically important).

For risk-adjustment purposes in value-based care, the epistaxis encounter represents an opportunity to document and confirm active comorbidities. All chronic conditions being managed or monitored at the encounter should be reported.

Code Tree / Related Procedure Codes

Understanding the entire nasal hemorrhage code family and its interactions with the endoscopic sinus code family is essential for accurate epistaxis coding.

  Nasal Hemorrhage Control — CPT 30901-30906
│
├── ANTERIOR EPISTAXIS CONTROL
│   ├── 30901 — Control nasal hemorrhage, anterior, SIMPLE (limited cautery and/or packing) any method
│   │            wRVU ~1.62 | 0-day global | Unilateral
│   │            Use for: single application silver nitrate, single small sponge pack, limited effort
│   │
│   └── 30903 — Control nasal hemorrhage, anterior, COMPLEX (extensive cautery and/or packing) any method ← THIS CODE
│                wRVU 3.00 | 0-day global | Unilateral
│                Use for: multiple failed attempts, layered packing, multiple bleeding sites anterior cavity,
│                extensive ribbon gauze packing, epistaxis balloon, brisk arterial-type bleeds
│
├── POSTERIOR EPISTAXIS CONTROL
│   ├── 30905 — Control nasal hemorrhage, posterior, with posterior nasal packs and/or cautery; initial
│   │            wRVU ~3.01 | 0-day global | Bilateral by nature (do NOT use Modifier 50)
│   │            Use for: FIRST encounter requiring posterior packing; source posterior to mid-cavity
│   │            NCCI NOTE: 30901 and 30903 are bundled INTO 30905 — when anterior and posterior
│   │            packing performed same-side same-session, report 30905 only
│   │
│   └── 30906 — Control nasal hemorrhage, posterior, with posterior nasal packs and/or cautery; subsequent
│                wRVU ~3.88 | 0-day global | Bilateral by nature (do NOT use Modifier 50)
│                Use for: REPEAT posterior packing at a SUBSEQUENT encounter for recurrence
│                NCCI NOTE: 30905 is bundled INTO 30906 — report 30906 for the return visit, not 30905
│
├── ENDOSCOPIC HEMORRHAGE CONTROL
│   └── 31238 — Nasal/sinus endoscopy, surgical; with control of nasal hemorrhage
│                wRVU varies | 0-day global
│                Use when endoscope is used AS THE OPERATIVE INSTRUMENT for hemorrhage control (not
│                merely for visualization). Does NOT bundle with 30901-30906 when used for separate
│                therapeutic intervention. However, 31231 (diagnostic endoscopy) IS bundled with
│                30903 and should not be separately reported when used only to locate the bleeding site.
│
├── NASOPHARYNGEAL HEMORRHAGE (distinct from nasal)
│   ├── 42970 — Control of nasopharyngeal hemorrhage, primary or secondary; simple, with posterior nasal pack
│   ├── 42971 — Control of nasopharyngeal hemorrhage; complicated, requiring general anesthesia
│   └── 42972 — Control of nasopharyngeal hemorrhage; with secondary surgical intervention
│                These codes apply to bleeding originating from the nasopharynx — distinct from nasal cavity
│
├── ENDOSCOPIC CAUTERY / DESTRUCTION (separate from packing-based hemorrhage control)
│   ├── 31237 — Nasal/sinus endoscopy, surgical; with biopsy, polypectomy, or debridement
│   └── 30901/30903 vs. 31238 DECISION RULE (per AMA CPT Assistant July 2020)
│       └── If endoscope used only to FIND the bleeding site, then packing/cautery performed → Report 30903
│           If endoscope used as the OPERATIVE INSTRUMENT to directly stop the bleed → Report 31238
│           Coders should never report 31231 (diagnostic endoscopy) alongside 30903 — it is bundled
│
├── WHEN TO REPORT E/M ONLY (NO PROCEDURE CODE)
│   ├── Patient presents with nosebleed; examination performed; bleeding has stopped spontaneously with no
│   │   intervention → Report E/M only (e.g., 99213-99214 as appropriate with Modifier 25 if separate
│   │   from any other procedure)
│   ├── Cotton pledgets/gauze with topical anesthetic/decongestant placed temporarily for identification
│   │   purposes, then removed — no cautery performed, no packing left in place → Report E/M only per
│   │   AMA CPT Assistant July 2020 guidance
│   └── Basic pressure or ice applied in-office with resolution — no packing left, no cautery → E/M only
│
└── SPHENOPALATINE ARTERY LIGATION / EMBOLIZATION (for refractory cases)
├── 30920 — Ligation arteries, ethmoidal
└── Interventional radiology sphenopalatine embolization → IR procedure codes (75894, 75898 etc.)
Note: Surgical ligation / embolization for refractory epistaxis represents a distinct escalation
beyond packing/cautery and is reported with the appropriate surgical or IR codes, not 30903.

NCCI Note:

30905 is bundled INTO 30906. For a return visit with recurrence, report 30906 only — never 30905 for a repeat encounter.

Includes / What This Code Covers

  • Control of active anterior nasal hemorrhage using extensive or complex techniques, including but not limited to: multiple silver nitrate applications, extended electrocauterization (mono- or bipolar), deep cauterization of anterior cavity bleeding sites not easily accessible, layered petroleum jelly-impregnated ribbon gauze packing, placement of prefabricated PVA nasal sponge (Merocel) with or without supplemental packing, placement of epistaxis balloon (RhinoRocket, Rapid Rhino), use of oxidized cellulose (Surgicel) with overlying packing, and topical thrombin application with absorbable packing substrate
  • Multiple methods used within the same encounter on the same side, provided the overall effort reflects “extensive” intervention per provider documentation
  • Procedures performed with or without nasal endoscopy, provided the endoscope is used only for visualization purposes to identify the bleeding site (not as the operative instrument — see Excludes below)
  • Anesthesia preparation, including application and dwell time of topical vasoconstrictor and anesthetic pledgets, as part of the same encounter leading to definitive hemostatic intervention — these preparatory steps are included in the procedural fee and not separately reportable
  • Post-procedure assessment of hemostasis on the same date of service — included in the 0-day global
  • For unilateral procedures: a single side of the nasal cavity; Modifier 50 or RT/LT is required for the contralateral side

Excludes / What This Code Does NOT Cover

  • Posterior epistaxis — when the bleeding source is posterior to the mid-nasal cavity, requires posterior nasal packing, or cannot be controlled with anterior measures alone, CPT 30905 (initial) or 30906 (subsequent) is the correct code. NCCI edits bundle 30901 and 30903 into 30905 for the same side in the same session — when anterior packing fails and posterior packing is also placed, report only 30905.
  • Simple anterior hemorrhage control (30901) — when only limited intervention is required (single silver nitrate application, single sponge pack with immediate resolution, straightforward easily controlled bleed), 30901 is the appropriate code. Using 30903 for a simple encounter is upcoding.
  • E/M only situations — when no cautery is performed and no packing is left in place, 30903 (and 30901) cannot be reported. Per AMA CPT Assistant July 2020, placing topical anesthetic pledgets temporarily to locate the site, then removing them when no active bleeding is found and no cauterization is performed, is an E/M service only.
  • Diagnostic nasal endoscopy (31231) as a companion code to 30903 — NCCI edits bundle 31231 into 30903. When diagnostic nasal endoscopy is performed solely to identify the anterior bleeding site before cauterization or packing, 31231 is not separately reportable.
  • Endoscopic hemorrhage control (31238) — when the scope IS the operative instrument — 31238 is separately reportable (instead of or in addition to 30903) only when the endoscope itself is used as the operative instrument to directly control bleeding. When the endoscope is merely used for visualization and the actual hemostatic intervention is performed with separate instrumentation, 30903 applies and 31238 is not used.
  • Sphenopalatine artery ligation or embolization — these are entirely distinct procedures for refractory epistaxis involving surgical ligation (30920) or interventional radiology embolization, not anterior packing/cautery procedures captured by 30903.
  • Post-operative epistaxis coded as R04.0 — epistaxis arising as a complication of a recent surgical procedure should be coded with T88.8XXA as the principal diagnosis, not R04.0 alone. This is an ICD-10-CM sequencing rule, not a CPT code restriction.
  • Removal of previously placed nasal packing at a subsequent visit — removal of anterior packing placed at a prior encounter is included in the global period only on the day of the procedure (0-day global). A subsequent visit for packing removal by the same physician is separately billable as an E/M service, since the 0-day global does not include follow-up care on subsequent days.
  • Any method that achieves hemostasis without cautery or packing — per CPT guidelines, the code family 30901-30905 requires that cautery was performed or packing was left in place. Direct pressure, ice, digital compression, or brief topical vasoconstrictors without subsequent cautery or retained packing do not meet the threshold for reporting any code in this family.

NCCI Edits and Bundling Considerations

  • 30901 and 30903 bundled into 30905 (same side, same session): This is the most important NCCI edit for epistaxis coding. When anterior hemorrhage control is attempted and fails, and posterior packing is subsequently placed in the same session on the same side, only 30905 is reportable. The anterior attempt is considered included in the posterior packing encounter. This cannot be overridden with Modifier 59.
  • 30905 bundled into 30906: At a subsequent encounter for the same patient’s continuing posterior epistaxis, 30906 is reported alone — 30905 should not be additionally reported for the same side at the same encounter.
  • 31231 (diagnostic nasal endoscopy) bundled into 30903: When diagnostic scope is used only to identify the bleeding site, it is considered a component of 30903 and not separately reportable. Only 31238 (therapeutic endoscopic hemorrhage control) may be separately considered, and only when it represents a distinct therapeutic endoscopic service beyond the non-endoscopic packing/cautery.
  • 30903 with E/M same day: An E/M service on the same date as 30903 may be separately reportable IF the E/M is significant and separately identifiable from the procedure — typically when the physician also evaluated and managed a separate medical condition or performed a more comprehensive evaluation that was distinct from the epistaxis treatment decision. Modifier 25 must be applied to the E/M code, and a separate medical problem must be documented as the basis for the E/M. For example, if the ENT also adjusted the patient’s antihypertensive medications during the same visit, 99213-25 (with I10 linked) could be reported alongside 30903 (with R04.0 linked).
  • 30901 and 30903 same side, same session: These are mutually exclusive on the same side. Only one code in the family can be reported per nasal cavity per encounter. If simple cautery is attempted first and then complex packing is placed in the same session on the same side, the more extensive code (30903) is the only code reported.
  • Different codes on different sides (same session): When different levels of intervention are required on each side in the same session (e.g., complex packing on the left, simple cautery on the right), both 30903 and 30901 may be reported, with Modifier 59 or XS on the lesser code, and laterality modifiers (LT/RT) on each as appropriate. This is an exception to the general NCCI bundling rule because these represent two distinct anatomic structures.

Modifiers

  • -50 (Bilateral Procedure) — Applied to 30903 when complex anterior hemorrhage control is performed on both sides of the nose in the same session. Report 30903-50 as a single line item. Some payers prefer two separate line items — 30903-LT and 30903-RT — verify with individual payer. Reminder: 30905 and 30906 are bilateral by nature and should never have Modifier 50 added.
  • -LT / -RT (Left Side / Right Side) — Laterality modifiers indicating which side was treated. Required by some payers and recommended as secondary modifiers with Modifier 50 by others. Laterality documentation in the medical record is essential to support these modifiers.
  • -25 (Significant, Separately Identifiable E/M on Same Day) — Applied to the E/M code when a separately identifiable evaluation and management service for a different condition is provided on the same day as 30903. Applied to the E/M code, not to 30903.
  • -59 / -XS (Distinct Procedural Service / Separate Structure) — Applied to 30901 (the lesser code) when 30901 and 30903 are both billed on the same date for different sides, to indicate a separate anatomic structure.
  • -52 (Reduced Services) — Applied to 30903 when the procedure was initiated but not completed as described (e.g., packing was placed but had to be immediately removed due to patient intolerance before hemostasis was confirmed).
  • -76 (Repeat Procedure by Same Physician) — Applied when 30903 must be repeated on the same calendar date by the same physician due to recurrent hemorrhage. Documents that the second procedure is not a duplicate claim but rather a second distinct procedure on the same date.
  • -77 (Repeat Procedure by Different Physician) — Applied when the same procedure (30903) is performed on the same date by a different physician than the original treating provider.
  • -22 (Increased Procedural Services) — May be appropriate in unusually complex cases, such as severely scarred nasal anatomy post-radiation, HHT with diffuse mucosal telangiectasia requiring extensive multi-site cauterization, or hemodynamically significant epistaxis requiring extensive packing with multiple pack types and prolonged procedure time. Documentation must clearly describe the exceptional nature of the service to support Modifier 22. A cover letter explaining the unusual circumstances is advisable when submitting claims with Modifier 22.

Documentation Requirements

The most significant documentation challenge with CPT 30903 is establishing the “complex” or “extensive” nature of the procedure compared to the simpler threshold of 30901. Because CPT explicitly does not define a numerical threshold for this distinction, the medical record must paint a clear clinical picture that supports the complexity claimed. The following elements should be present:

  1. Bleeding site location — anterior confirmation. The note must document or imply that the source was anterior (e.g., “bleeding visualized on the anterior nasal septum at Little’s area,” “anterior rhinoscopy with nasal speculum revealed active bleeding at Kiesselbach’s plexus”). If the source is described as posterior or indeterminate, the appropriate posterior or escalated code should be considered.
  2. Method or methods used. Every technique employed should be documented: “silver nitrate cauterization applied three times to the septal bleeding point without sustained hemostasis, followed by placement of a 4 cm Merocel sponge with thrombin-soaked gelfoam anteriorly.” This level of detail clearly establishes the extensive, layered nature of the intervention.
  3. Number of attempts and techniques. If multiple methods were attempted sequentially (cautery first, then packing after cautery alone failed), this should be explicitly documented. The sequential failure of simpler measures before escalating to more aggressive packing is among the strongest indicators of complexity.
  4. Laterality. Right, left, or bilateral should be clearly documented for each technique applied.
  5. Hemostasis confirmation. Documentation that the intervention achieved hemostasis (e.g., “nasal cavity inspected after packing placement — no active bleeding observed”) confirms that the procedure was complete.
  6. Discharge instructions and follow-up plan. For packing placed to remain in situ, documentation of instructions given to the patient (e.g., “patient instructed to return in 48 hours for packing removal,” “patient to follow up in 3 days”) provides clinical coherence and supports the overall encounter complexity.
  7. Underlying conditions. When epistaxis is secondary to a known condition (hypertension, anticoagulation, coagulopathy, HHT), this should be documented explicitly and linked clinically to the bleeding presentation.

Coding Examples

Example 1 — Straightforward Complex Anterior Epistaxis, Unilateral An established ENT patient presents with persistent left anterior epistaxis unresponsive to home pressure and online advice for 45 minutes. The ENT applies oxymetazoline-soaked cotton pledgets bilaterally for 10 minutes. After removal, brisk arterial-type bleeding is still visible from Little’s area of the left nasal septum. Silver nitrate cauterization is applied four times over a 2 cm area without sustained hemostasis. A Merocel sponge is then placed into the left anterior nasal cavity with thrombin-soaked Gelfoam layered anterior to the sponge. Hemostasis confirmed. Patient discharged with instructions to return in 48 hours for sponge removal.

CPT: 30903-LT Diagnosis: R04.0 (Epistaxis) Note: The sequential use of four silver nitrate applications followed by layered packing clearly supports the “extensive” threshold for 30903 over 30901. The preparation with oxymetazoline pledgets is included in the procedure fee and is not separately reportable.

Example 2 — Bilateral Anterior Epistaxis, Both Sides Complex A patient on warfarin with a supratherapeutic INR presents with bilateral anterior epistaxis that he has been unable to control at home. The ENT evaluates both nasal cavities and finds active bleeding bilaterally from the anterior septum. Bilateral nasal packing with petroleum jelly-impregnated ribbon gauze is placed, requiring approximately 45 cm of ribbon gauze per side layered in accordion fashion. Hemostasis confirmed bilaterally.

CPT: 30903-50 Diagnoses: R04.0 (Epistaxis — primary, linked to 30903), T45.515A (Adverse effect of anticoagulants, initial encounter), Z79.01 (Long-term (current) use of anticoagulants) Note: Modifier 50 indicates bilateral performance. Extensive ribbon gauze packing on both sides clearly supports 30903 over 30901. The adverse effect of anticoagulants is separately coded per ICD-10-CM adverse effect coding guidelines.

Example 3 — Different Complexity on Each Side, Same Session An emergency physician treats a patient with bilateral epistaxis. The right side responds immediately to a single silver nitrate application — limited intervention. The left side continues to bleed briskly despite two attempts at cauterization, ultimately requiring placement of an epistaxis balloon.

CPT: 30903-LT (complex, left side), 30901-RT-59 (simple, right side) Diagnosis: R04.0 linked to both procedure codes Note: Modifier 59 (or XS) on 30901-RT indicates a distinct structure from 30903-LT. Laterality modifiers convey the distinct sides. Because the NCCI bundles 30901 into 30903 only for the same side/same session, separate reporting is appropriate here.

Example 4 — Anterior Packing That Progresses to Posterior Packing — Wrong Code Scenario A patient presents with right anterior epistaxis. The ENT first attempts anterior packing with a PVA sponge. Bleeding continues posteriorly, and examination reveals posterior nasopharyngeal blood flow. The ENT proceeds to place a posterior balloon nasal pack on the right side to control the posterior source.

Correct CPT: 30905-RT only (initial posterior packing) Incorrect CPT: 30903-RT + 30905-RT (NCCI bundles 30901 and 30903 into 30905 — once posterior packing is placed, 30903 for the anterior attempt is included in 30905 and cannot be separately reported for the same side in the same session)

Example 5 — No Procedure Code — E/M Only An established patient is seen in the ENT office for a nosebleed. The ENT applies cotton pledgets soaked in oxymetazoline and lidocaine for 10 minutes to achieve anesthesia and vasoconstriction. On removing the pledgets, no active bleeding site is identified. No cauterization is performed. No packing is left in place. The ENT counsels the patient on nasal hygiene, humidification, and petroleum jelly application to the septum.

CPT: 99213 (or 99214 depending on MDM complexity) — E/M only. No procedure code. Diagnosis: R04.0 Rationale: Per AMA CPT Assistant July 2020 guidance, when cotton/gauze pledgets are placed temporarily with topical agents and removed without active cautery being performed and without packing being left in place, the service is an E/M only. Reporting 30901 or 30903 in this scenario is a false claim.

Example 6 — Inpatient Coder Scenario — PCS Code Selection A patient with known HHT (Osler-Weber-Rendu syndrome) is admitted for refractory epistaxis requiring blood transfusion. The ENT performs nasal cauterization targeting multiple bilateral anterior septal telangiectasias using a bipolar electrocautery probe. The primary intent is destruction of the telangiectatic vessels, not simply stopping acute bleeding. Extensive bilateral cauterization of discrete septal vascular lesions is performed.

ICD-10-PCS: 09590ZZ (Destruction of Nasal Septum, Open Approach) — applicable bilaterally; per PCS guideline B3.7, when cauterization is the definitive targeted destruction of specific vascular structures (not merely stopping acute bleeding), Destruction is the appropriate root operation over Control. Principal Diagnosis: I78.0 (HHT) Secondary Diagnoses: R04.0 (Epistaxis), D64.9 (Anemia), Z51.3 (Encounter for blood transfusion) DRG: Because 09590ZZ is OR-designated, the case will group to a surgical DRG — likely MS-DRG 133 or 134 (Other ENT O.R. Procedures with or without CC/MCC), rather than the medical epistaxis DRGs 154-156.

Coding Pitfalls and Common Errors

  • Upcoding 30903 when documentation only supports 30901: The single most frequent compliance issue in epistaxis coding. If the documentation reflects a single silver nitrate application to a clearly visible bleeding point with immediate resolution, only 30901 is supported. Using 30903 routinely for all nosebleed encounters regardless of documented complexity is a coding pattern that frequently surfaces in payer audits of ENT and ED practices.
  • Reporting both 30901 and 30903 for the same side in the same session: These are mutually exclusive on the same side. NCCI edits will deny the lesser code. Report only the most extensive code for a given nostril per encounter.
  • Reporting 30901 or 30903 when no packing was left in place and no cautery was performed: Per AMA CPT Assistant July 2020, cotton pledgets placed temporarily for localization purposes, then removed without cauterization or retained packing, constitute an E/M-only encounter. This is a well-documented false claims risk in emergency medicine coding.
  • Failing to add Modifier -50 or laterality modifiers for bilateral procedures: Reporting 30903 twice on two separate lines without modifier 50 or laterality modifiers creates a duplicate claim appearance and will typically be denied. Use 30903-50 or 30903-LT/30903-RT-59 per payer preference.
  • Reporting 30903 and 30905 on the same side in the same session: NCCI bundles anterior codes into posterior codes for the same structure in the same session. When the encounter escalates to posterior packing, report only 30905.
  • Reporting 31231 (diagnostic endoscopy) with 30903: NCCI bundles diagnostic nasal endoscopy into all epistaxis control codes. Do not separately report 31231 when it was used only to locate the bleeding site prior to 30903 treatment.
  • Using R04.0 for post-operative epistaxis: Epistaxis as a complication of a surgical procedure should be coded with T88.8XXA (or the specific surgical complication code), not R04.0. Using R04.0 for post-operative epistaxis misses the complication relationship and may have DRG and quality reporting implications in the inpatient setting.
  • Inpatient PCS — using Control (0W3Q7ZZ) when Packing (2Y41X52) or Destruction (09590ZZ) is more specific: PCS Guideline B3.7 directs coders to use the more definitive root operation when available. Defaulting to Control for all epistaxis procedures without analyzing the method used will result in coding inaccuracy and potential DRG impact.

Graph View

Recent Notes